Court blocks mail-order abortion pill access nationwide, upending telehealth care

Patients seeking abortion pills will have to find an in-person clinic again, even in states where abortion remains legal, after a federal appeals court blocked telehealth dispensing and mail delivery of mifepristone nationwide.

The New Orleans-based 5th U.S. Circuit Court of Appeals issued the order on May 1, 2026, requiring the drug to be distributed only in person at clinics while Louisiana’s challenge moves forward. The ruling targets the Food and Drug Administration’s January 3, 2023 modification of mifepristone’s risk-management rules, which had allowed the drug to be prescribed through telemedicine and delivered by mail.

That change had become central to abortion access in a country where medication abortion now makes up the majority of care. The Guttmacher Institute estimated about 642,700 medication abortions in 2023, or 63% of all abortions in the formal health care system. Mifepristone, first approved by the FDA in 2000 and later cleared for use through 10 weeks of gestation in 2016, has been used by millions of Americans since approval.

The practical effect of the appeals court order is immediate and broad. Patients who previously received pills by mail after a telehealth visit may now have to arrange clinic appointments, travel farther, take time off work and secure child care or transportation to comply with an in-person requirement. Those burdens are likely to fall hardest on people in rural areas, patients with limited money and patients in states with abortion bans, where crossing state lines may be the only option. The American Civil Liberties Union said the ruling reinstates a nationwide in-person requirement that the FDA had lifted in 2021, while Physicians for Reproductive Health said telehealth access is no longer available for abortion care nationally.

The decision also sharpens the clash between state attorneys general and federal drug regulators. Louisiana filed the lawsuit in federal court in December 2025, according to the state attorney general’s office, arguing that the FDA’s telehealth and mail policies undermine state authority. Louisiana officials have said the challenge is aimed at the 2023 federal rule allowing pills to be mailed into the state.

The case arrives after the U.S. Supreme Court in June 2024 dismissed an earlier mifepristone challenge for lack of standing, leaving the drug’s approval intact but not settling the broader fight over access. Now the Fifth Circuit has put a nationwide brake on the very distribution system that made medication abortion easier to obtain, setting up another round of conflict over how far the FDA’s authority reaches when courts and states push back.